View of GLP-1 RECEPTOR AGONISTS AND SGLT-2 INHIBITORS BEYOND GLYCEMIC CONTROL: CARDIOVASCULAR BENEFITS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

Return to Issue Details GLP-1 RECEPTOR AGONISTS AND SGLT-2 INHIBITORS BEYOND GLYCEMIC CONTROL: CARDIOVASCULAR BENEFITS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS Download Download PDF